IonQ heads into its May 6 Q1 results as one of the most heavily shorted names in the US market — yet a 60% price surge over the past month has left the short book deeply offside.
The short position is both large and structurally tight. Short interest runs at 23.5% of the free float — ranked in the second percentile of the entire universe, meaning almost no stock in the market is more shorted. Availability has dropped to a level indicating extreme strain in the lending pool: utilization has been running above 96% for most of April, with brief spikes to 100% earlier in the month, close to the 52-week maximum. Yet the cost to borrow has eased to roughly 1.5% APR, well below its April peak near 3% — suggesting that while shares are scarce, forced liquidations have not yet driven borrow pricing sharply higher. Days to cover stand at 6.5, meaning shorts would need more than a full trading week of average volume to exit cleanly.
Options positioning turned more defensive into the print. The put/call ratio moved to 1.04 on Friday, running about 1.6 standard deviations above its 20-day average of 0.90 — the most protective reading since late March. That shift is notable in context: through most of April, as the stock rallied, the PCR was declining toward its 52-week low of 0.75, suggesting bulls dominated the options market during the run-up. The recent reversal hints that some traders are now buying downside cover after the 60% monthly gain.
The analyst community is split on how much the valuation has outrun the story. Bulls point to $132M in bookings — already more than half of the company's $235M midpoint 2026 revenue guidance — as evidence that commercial momentum is real. They also argue IonQ's trapped-ion architecture and modular design differentiate it for fault-tolerant quantum computing at scale. Bears push back on scalability risk and the intensifying threat from better-resourced competitors entering the trapped-ion space. The Street's aggregate target averages around $64.55, implying roughly 40% upside from current levels. The most recent fresh action came from Northland Capital Markets, which initiated coverage at Outperform with a $55 target in mid-April — below the current consensus, reflecting some caution on near-term execution. Most other changes in the data are from late February, following the prior earnings release, when several firms trimmed targets even while holding Buy ratings.
Institutional holders also added aggressively into Q1. Vanguard and BlackRock each increased their positions by more than 5 million and 7.5 million shares respectively in the quarter ending March 31 — sizable additions relative to their prior stakes. That institutional building contrasts with a steady pattern of small insider sales over the same period, with the CEO, CFO, and Executive Chairman all selling modest blocks in March and April.
Past earnings reactions have been sharply positive: the February 2026 print drove a 29% one-day gain and extended to a 17% five-day move. The print on May 6 will test whether commercial bookings momentum has accelerated enough to justify a stock that has now more than doubled from its early-year lows — or whether the short book finds its catalyst.
See the live data behind this article on ORTEX.
Open IONQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
